This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Carlos:
Google provided us with with the following answer to your question:
Elevate Decisions in Prostate Cancer Care Using Genomic Precision
The Oncotype DX® family of prostate cancer tests applies advanced genomics to help guide your most important choices for active surveillance, surgery, and treatment.
Every patient is different. That means every tumor is different. With the genomic-based insights of the Oncotype DX tests, you can make informed decisions with data catered to each patient’s unique scenario.
